收藏切换
Efficacy and safety of apatinib monotherapy or in combination wtih duvarizumab in the treatment of advanced colorectal cancer
收藏切换
Ruiling DING, Yunchang YAO, Yao WANG*
World Clinical Drug | 2023, 44(6) : 614 - 620
Less
收藏切换
World Clinical Drug | 2023, 44(6): 614-620
• Article •
Efficacy and safety of apatinib monotherapy or in combination wtih duvarizumab in the treatment of advanced colorectal cancer
Full
Ruiling DING, Yunchang YAO, Yao WANG*
Affiliations
  • Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China
Published: 2023-06-10 doi: 10.13683/j.wph.2023.06.017
Outline
收藏切换
Objective

To evaluate the efficacy and safety of third-line treatment of duvarizumab combined with apatinib in the treatment of unresectable advanced colorectal cancer (CRC).

Methods

Sixty-six unresectable advanced CRC patients who received combination therapy (combination group, n=30) or apatinib monotherapy (monotherapy group, n=36) as third-line treatment were included. All patients were treated until intolerance or disease progression. The overall treatment response, objective response rate, disease control rate and incidence of adverse events were compared between the two groups.

Results

The overall response in the combination group was higher than that of the monotherapy group (P=0.025). The rates of complete response, partial response, stable disease, and disease progression in the combination group were 0, 26.67%, 50.00%, and 23.33%, respectively. Meanwhile, those in the monotherapy group were 0, 8.33%, 47.23%, and 44.44%, respectively. The objective response rate in the combination group was higher than that in the monotherapy group (26.67% vs 8.33%, P=0.047), but the difference was not statistically significant in disease control rate between the two groups (76.67% vs 55.56%, P=0.073). The progression-free survival (median: 8.60 months vs 4.50 months, P=0.012) and overall survival (median: 15.70 months vs 8.10 months, P=0.009) of combination group were superior to those of the monotherapy group. The incidence of adverse events in the combination group was similar to that in the monotherapy group (P>0.05). Most adverse events in the combination group were grade 1 - 2, and only 7 patients (23.33%) had grade 3 - 4 adverse events.

Conclusion

Third-line treatment of duvaliuzumab combined with apatinib could improve the response rate and prolong survival in patients with unresectable advanced CRC with an acceptable safety profile.

apatinib  /  duvarizumab  /  advanced colorectal cancer  /  efficacy  /  safety
丁瑞玲, 姚云昌, 王尧. 阿帕替尼单用或联合度伐利尤单抗治疗晚期结直肠癌的有效性和安全性研究. 世界临床药物, 2023 , 44 (6) : 614 -620 . DOI: 10.13683/j.wph.2023.06.017
Ruiling DING, Yunchang YAO, Yao WANG. Efficacy and safety of apatinib monotherapy or in combination wtih duvarizumab in the treatment of advanced colorectal cancer[J]. World Clinical Drug, 2023 , 44 (6) : 614 -620 . DOI: 10.13683/j.wph.2023.06.017
Year 2023 volume 44 Issue 6
11
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.06.017
  • Receive Date:2022-12-09
  • Online Date:2026-11-18
  • Published:2023-06-10
Article Data
Affiliations
History
  • Received:2022-12-09
Affiliations
    Department of Pharmacy, Ordos Central Hospital, Ordos 017010, Inner Mongolia Autonomous Region, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.06.017
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT